COHERUS BIOSCIENCES INC. - COMMON STOCK

Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022

29 апр 2022 08:45:00 Источник Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States

14 апр 2022 08:30:00 Источник Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting

08 апр 2022 13:10:45 Источник Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

05 апр 2022 16:30:00 Источник Nasdaq GlobeNewswire

Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event

29 мар 2022 09:15:00 Источник Nasdaq GlobeNewswire

Coherus BioSciences to Highlight New Product Pipeline, Cancer Immunotherapy Development Plans at March 29, 2022 Analyst Day Event

22 мар 2022 16:30:24 Источник Nasdaq GlobeNewswire

Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer

15 мар 2022 08:00:02 Источник Nasdaq GlobeNewswire

Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series

15 мар 2022 07:30:00 Источник Nasdaq GlobeNewswire

Coherus Management to Present at Upcoming Investor Conferences

04 мар 2022 16:05:00 Источник Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell

04 мар 2022 08:00:00 Источник Nasdaq GlobeNewswire

Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results

17 фев 2022 16:01:00 Источник Nasdaq GlobeNewswire

Coherus Names Paul Reider Chief Commercial Officer

15 фев 2022 16:30:00 Источник Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

14 фев 2022 08:30:00 Источник Nasdaq GlobeNewswire

Coherus BioSciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 17th, 2022

11 фев 2022 08:30:00 Источник Nasdaq GlobeNewswire

Coherus BioSciences Appoints Health Care Payer Expert Lee N. Newcomer, M.D., to Board of Directors

07 фев 2022 08:30:01 Источник Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody

10 янв 2022 07:30:00 Источник Nasdaq GlobeNewswire

Coherus BioSciences Secures Credit Financing with Pharmakon Advisors

07 янв 2022 08:30:00 Источник Nasdaq GlobeNewswire

Coherus BioSciences Management to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 янв 2022 08:32:50 Источник Nasdaq GlobeNewswire

Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)

20 дек 2021 07:59:00 Источник Nasdaq GlobeNewswire

Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer

17 дек 2021 09:09:17 Источник Nasdaq GlobeNewswire